NHS patients will be the first in Europe to benefit from a ground-breaking, non-invasive liver cancer treatment, as the Government’s Plan for Change slashes burdensome red tape and drives innovation, establishing Britain’s role as a medical technology powerhouse.

Using ultrasound technology, the device – developed by US-based company HistoSonics – destroys tumours without surgery, scalpels, radiation, with minimal damage to surrounding organs.

Patients stand to benefit from faster recovery times, potentially greater survival rates, fewer potentially dangerous complications, and less hospital stays – helping to cut waits for others – all marking a new era in cancer treatment.

Ongoing research is exploring its potential to transform treatment for other hard-to-reach tumours – including kidney and pancreatic cancers – bringing hope to even more NHS patients in the future.

Treatment is delivered via a single short session – potentially taking no longer than 30 minutes – with limited or no pain, a quick recovery, and can be performed as a day case.

As the Government busts the bureaucracy holding back public services and stifling innovation, Health and Social Care Secretary Wes Streeting granted authorisation for controlled early access to the device via an unmet clinical need authorisation. Available through the UK’s Innovative Devices Access Pathway programme, a government-funded scheme to get cutting-edge health innovations to the market much quicker, NHS patients can benefit from technology years earlier than planned.

 Health and Social Care Secretary Wes Streeting said:

Bureaucracy has become a handbrake on ambition, stopping innovation in its tracks and holding our health service back.

But through our Plan for Change, we are slashing red tape, so game-changing new treatments reach the NHS front line quicker – transforming healthcare.  

Regulation is vital to protect patients. However, as the pace of innovation ramps up, our processes must be more agile to help speed the shift from analogue to digital.

Our common sense approach to regulation will streamline approval processes so countless more patients are liberated from life-limiting conditions.

The technology, called histotripsy, is being debuted at Addenbrooke’s Hospital in Cambridge, part of Cambridge University Hospital NHS Foundation Trust (CUH) with the first NHS patients being treated using the game-changing device this summer. The technology was procured and installed thanks to a generous donation to the University of Cambridge from the Li Ka Shing Foundation, which has been a longstanding supporter of cancer research at the University.

Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said:

Through his longstanding support of cancer research at Cambridge, Sir Ka-shing Li continues to make a significant impact on outcomes for cancer patients.

Cutting-edge technology such as this histotripsy machine allows Cambridge to remain at the forefront of understanding and treating cancer, a position we aim to strengthen further with Cambridge Cancer Research Hospital.

The Government’s Plan for Change  is focused on securing the UK’s position as a global tech powerhouse – including in healthcare – which fosters innovation to transform the lives of working people and deliver a decade of national renewal.

The move delivers on the Government’s commitment to tackle bureaucracy blocking investment and regulatory complexity that has previously stifled growth.

Roland Sinker, Chief Executive of Cambridge University Hospitals said:

Histotripsy is an exciting new technology that will make a huge difference to patients.

By offering this non-invasive, more targeted treatment we can care for more people as outpatients and free up time for surgeons to treat more complex cases.

The faster recovery times mean patients will be able to return to their normal lives more quickly, which will also reduce pressure on hospital beds, helping us ensure that patients are able to receive the right treatment at the right time.

We are delighted to be receiving this new state of the art machine.

Fiona Carey, Co-chair of the Patient Advisory Group for Cambridge Cancer Research Hospital and kidney cancer patient with advanced disease, said:

This is seriously good news. A new, non-invasive option to treat these cancers is very welcome indeed.

For patients for whom ordinary surgery is no longer an option, this could make all the difference.

James Pound, Interim Executive Director, Innovation and Compliance at MHRA, said:

This is a strong example of smart, agile regulation in action. Working closely with partners through the Innovative Devices Access Pathway, we’ve shown we can get promising technologies to patients faster – without compromising safety.

It’s a major step forward for patients with liver cancer and shows how the UK can be a frontrunner in supporting responsible innovation that meets real clinical need.